Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015

Description: Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015

Summary

This, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Respiratory
Syncytial Virus (RSV) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Respiratory Syncytial Virus (RSV) Infections Overview
Therapeutics Development
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
3-V Biosciences, Inc.
Ablynx NV
ADMA Biologics, Inc.
Agivax, Inc.
AlphaVax, Inc.
AmVac AG
Aridis Pharmaceuticals LLC
Artificial Cell Technologies, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bavarian Nordic A/S
Biota Pharmaceuticals, Inc.
Celltrion, Inc.
Codagenix, Inc.
Crucell N.V.
CureVac GmbH
Emergent BioSolutions Inc.
Evec, Inc.
F. Hoffmann-La Roche Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Humabs BioMed SA
iBio, Inc.
Immunovaccine, Inc.
Johnson & Johnson
Kineta, Inc.
MedImmune, LLC
Medivir AB
Merck & Co., Inc.
Microbiotix, Inc.
MSM Protein Technologies, Inc.
Mucositis B.V.
NanoBio Corporation
Naxgen Pharmaceuticals, Inc.
Novavax, Inc.
Panacea Biotech Limited
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
AK-0529 - Drug Profile
ALS-8112 - Drug Profile
ALS-8176 - Drug Profile
ALX-0171 - Drug Profile
AMV-601 - Drug Profile
AMV-602 - Drug Profile
AMV-603 - Drug Profile
AMV-611 - Drug Profile
AR-201 - Drug Profile
AZ-27 - Drug Profile
BTAC-585 - Drug Profile
danirixin - Drug Profile
DPX-RSV - Drug Profile
Drugs to Inhibit STAT for RSV Infection - Drug Profile
EV-046120 - Drug Profile
EV-046135 - Drug Profile
GBV-006 - Drug Profile
GSK-3003891A - Drug Profile
GV-2311 - Drug Profile
human parainfluenza virus [type 1] + respiratory syncytial virus vaccine - Drug Profile
IKT-041 - Drug Profile
influenza + RSV vaccine - Drug Profile
JNJ-53718678 - Drug Profile
JNJ-61187191-AAA - Drug Profile
MBX-300 - Drug Profile
MEDI-7510 - Drug Profile
MEDI-8897 - Drug Profile
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile
Monoclonal Antibody for RSV Infections - Drug Profile
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile
MPE-8 - Drug Profile
MSM-605 - Drug Profile
MVA-BN-RSV - Drug Profile
MVA-RSV - Drug Profile
Oligonucleotide for Respiratory Syncytial Viral Infections - Drug Profile
palivizumab biosimilar - Drug Profile
palivizumab biosimilar - Drug Profile
palivizumab biosimilar - Drug Profile
pertussis [strain BPZE1] vaccine - Drug Profile
presatovir - Drug Profile
Recombinant Protein for RSV Infections - Drug Profile
REGN-2222 - Drug Profile
REP-9 - Drug Profile
Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlphaVax, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AmVac AG, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Astellas Pharma Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Biota Pharmaceuticals, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Crucell N.V., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by CureVac GmbH, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Microbiotix, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MSM Protein Technologies, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by REPLiCor Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart, Inc., H1 2015
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2015
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H1 2015
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H1 2015
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2015
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3338387/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3338387/">http://www.researchandmarkets.com/reports/3338387/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCH3FXXK</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>☐</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>____________________</td>
<td>Last Name:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>____________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World